High rates of ovarian function preservation after hematopoietic cell transplantation with melphalan-based reduced intensity conditioning for pediatric acute leukemia: an analysis from the Japan Association of Childhood Leukemia Study (JACLS)

Hisanori Fujino, Hiroyuki Ishida, Akihiro Iguchi, Masaei Onuma, Koji Kato, Mariko Shimizu, Masahiro Yasui, Hiroyuki Fujisaki, Kazuko Hamamoto, Kana Washio, Hirotoshi Sakaguchi, Emiko Miyashita, Yuko Osugi, Etsuko Nakagami-Yamaguchi, Akira Hayakawa, Atsushi Sato, Yoshiyuki Takahashi, Keizo Horibe

Research output: Contribution to journalArticle

Abstract

Women are at high risk of hypergonadotropic hypogonadism after hematopoietic cell transplantation (HCT). Hypogonadism is universal after irradiation or busulfan. We hypothesized that reduced intensity conditioning (RIC) might protect ovarian function after HCT. We retrospectively reviewed data from patients with acute leukemia treated according to the Japan Association of Childhood Leukemia Study and nationwide multicenter study protocol. We selected 11 female patients with acute leukemia who received first HCT with RIC, had survived for three or more years after HCT, and were aged ≥ 12 years at the last follow-up visit. Median age at diagnosis, HCT, and last visit were 8, 10, and 17 years. Six patients received HLA-matched bone marrow (BM), two HLA-mismatched BM, and three cord blood. Melphalan was used as conditioning regimen in all patients. At the last visit, six of seven post-pubertal patients at transplantation recovered menstruation, and four of four patients who underwent transplantation at the pre-pubertal began menstruation. Height z scores showed no significant reduction between pre-transplant and post-transplant. No patients received growth hormone treatment. Only one recipient displayed subclinical hypothyroidism. Melphalan-based RIC may be an encouraging option for patients with acute leukemia to avoid ovarian and endocrine dysfunction after HCT.

Original languageEnglish
JournalInternational journal of hematology
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Melphalan
Cell Transplantation
Japan
Leukemia
Pediatrics
Hypogonadism
Menstruation
Transplantation
Bone Marrow
Transplants
Busulfan
Hypothyroidism
Fetal Blood
Growth Hormone
Multicenter Studies

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

High rates of ovarian function preservation after hematopoietic cell transplantation with melphalan-based reduced intensity conditioning for pediatric acute leukemia : an analysis from the Japan Association of Childhood Leukemia Study (JACLS). / Fujino, Hisanori; Ishida, Hiroyuki; Iguchi, Akihiro; Onuma, Masaei; Kato, Koji; Shimizu, Mariko; Yasui, Masahiro; Fujisaki, Hiroyuki; Hamamoto, Kazuko; Washio, Kana; Sakaguchi, Hirotoshi; Miyashita, Emiko; Osugi, Yuko; Nakagami-Yamaguchi, Etsuko; Hayakawa, Akira; Sato, Atsushi; Takahashi, Yoshiyuki; Horibe, Keizo.

In: International journal of hematology, 01.01.2019.

Research output: Contribution to journalArticle

Fujino, H, Ishida, H, Iguchi, A, Onuma, M, Kato, K, Shimizu, M, Yasui, M, Fujisaki, H, Hamamoto, K, Washio, K, Sakaguchi, H, Miyashita, E, Osugi, Y, Nakagami-Yamaguchi, E, Hayakawa, A, Sato, A, Takahashi, Y & Horibe, K 2019, 'High rates of ovarian function preservation after hematopoietic cell transplantation with melphalan-based reduced intensity conditioning for pediatric acute leukemia: an analysis from the Japan Association of Childhood Leukemia Study (JACLS)', International journal of hematology. https://doi.org/10.1007/s12185-019-02627-9
Fujino, Hisanori ; Ishida, Hiroyuki ; Iguchi, Akihiro ; Onuma, Masaei ; Kato, Koji ; Shimizu, Mariko ; Yasui, Masahiro ; Fujisaki, Hiroyuki ; Hamamoto, Kazuko ; Washio, Kana ; Sakaguchi, Hirotoshi ; Miyashita, Emiko ; Osugi, Yuko ; Nakagami-Yamaguchi, Etsuko ; Hayakawa, Akira ; Sato, Atsushi ; Takahashi, Yoshiyuki ; Horibe, Keizo. / High rates of ovarian function preservation after hematopoietic cell transplantation with melphalan-based reduced intensity conditioning for pediatric acute leukemia : an analysis from the Japan Association of Childhood Leukemia Study (JACLS). In: International journal of hematology. 2019.
@article{265fce35d6234f62a38eb8647f686572,
title = "High rates of ovarian function preservation after hematopoietic cell transplantation with melphalan-based reduced intensity conditioning for pediatric acute leukemia: an analysis from the Japan Association of Childhood Leukemia Study (JACLS)",
abstract = "Women are at high risk of hypergonadotropic hypogonadism after hematopoietic cell transplantation (HCT). Hypogonadism is universal after irradiation or busulfan. We hypothesized that reduced intensity conditioning (RIC) might protect ovarian function after HCT. We retrospectively reviewed data from patients with acute leukemia treated according to the Japan Association of Childhood Leukemia Study and nationwide multicenter study protocol. We selected 11 female patients with acute leukemia who received first HCT with RIC, had survived for three or more years after HCT, and were aged ≥ 12 years at the last follow-up visit. Median age at diagnosis, HCT, and last visit were 8, 10, and 17 years. Six patients received HLA-matched bone marrow (BM), two HLA-mismatched BM, and three cord blood. Melphalan was used as conditioning regimen in all patients. At the last visit, six of seven post-pubertal patients at transplantation recovered menstruation, and four of four patients who underwent transplantation at the pre-pubertal began menstruation. Height z scores showed no significant reduction between pre-transplant and post-transplant. No patients received growth hormone treatment. Only one recipient displayed subclinical hypothyroidism. Melphalan-based RIC may be an encouraging option for patients with acute leukemia to avoid ovarian and endocrine dysfunction after HCT.",
author = "Hisanori Fujino and Hiroyuki Ishida and Akihiro Iguchi and Masaei Onuma and Koji Kato and Mariko Shimizu and Masahiro Yasui and Hiroyuki Fujisaki and Kazuko Hamamoto and Kana Washio and Hirotoshi Sakaguchi and Emiko Miyashita and Yuko Osugi and Etsuko Nakagami-Yamaguchi and Akira Hayakawa and Atsushi Sato and Yoshiyuki Takahashi and Keizo Horibe",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s12185-019-02627-9",
language = "English",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",

}

TY - JOUR

T1 - High rates of ovarian function preservation after hematopoietic cell transplantation with melphalan-based reduced intensity conditioning for pediatric acute leukemia

T2 - an analysis from the Japan Association of Childhood Leukemia Study (JACLS)

AU - Fujino, Hisanori

AU - Ishida, Hiroyuki

AU - Iguchi, Akihiro

AU - Onuma, Masaei

AU - Kato, Koji

AU - Shimizu, Mariko

AU - Yasui, Masahiro

AU - Fujisaki, Hiroyuki

AU - Hamamoto, Kazuko

AU - Washio, Kana

AU - Sakaguchi, Hirotoshi

AU - Miyashita, Emiko

AU - Osugi, Yuko

AU - Nakagami-Yamaguchi, Etsuko

AU - Hayakawa, Akira

AU - Sato, Atsushi

AU - Takahashi, Yoshiyuki

AU - Horibe, Keizo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Women are at high risk of hypergonadotropic hypogonadism after hematopoietic cell transplantation (HCT). Hypogonadism is universal after irradiation or busulfan. We hypothesized that reduced intensity conditioning (RIC) might protect ovarian function after HCT. We retrospectively reviewed data from patients with acute leukemia treated according to the Japan Association of Childhood Leukemia Study and nationwide multicenter study protocol. We selected 11 female patients with acute leukemia who received first HCT with RIC, had survived for three or more years after HCT, and were aged ≥ 12 years at the last follow-up visit. Median age at diagnosis, HCT, and last visit were 8, 10, and 17 years. Six patients received HLA-matched bone marrow (BM), two HLA-mismatched BM, and three cord blood. Melphalan was used as conditioning regimen in all patients. At the last visit, six of seven post-pubertal patients at transplantation recovered menstruation, and four of four patients who underwent transplantation at the pre-pubertal began menstruation. Height z scores showed no significant reduction between pre-transplant and post-transplant. No patients received growth hormone treatment. Only one recipient displayed subclinical hypothyroidism. Melphalan-based RIC may be an encouraging option for patients with acute leukemia to avoid ovarian and endocrine dysfunction after HCT.

AB - Women are at high risk of hypergonadotropic hypogonadism after hematopoietic cell transplantation (HCT). Hypogonadism is universal after irradiation or busulfan. We hypothesized that reduced intensity conditioning (RIC) might protect ovarian function after HCT. We retrospectively reviewed data from patients with acute leukemia treated according to the Japan Association of Childhood Leukemia Study and nationwide multicenter study protocol. We selected 11 female patients with acute leukemia who received first HCT with RIC, had survived for three or more years after HCT, and were aged ≥ 12 years at the last follow-up visit. Median age at diagnosis, HCT, and last visit were 8, 10, and 17 years. Six patients received HLA-matched bone marrow (BM), two HLA-mismatched BM, and three cord blood. Melphalan was used as conditioning regimen in all patients. At the last visit, six of seven post-pubertal patients at transplantation recovered menstruation, and four of four patients who underwent transplantation at the pre-pubertal began menstruation. Height z scores showed no significant reduction between pre-transplant and post-transplant. No patients received growth hormone treatment. Only one recipient displayed subclinical hypothyroidism. Melphalan-based RIC may be an encouraging option for patients with acute leukemia to avoid ovarian and endocrine dysfunction after HCT.

UR - http://www.scopus.com/inward/record.url?scp=85062995713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062995713&partnerID=8YFLogxK

U2 - 10.1007/s12185-019-02627-9

DO - 10.1007/s12185-019-02627-9

M3 - Article

C2 - 30864117

AN - SCOPUS:85062995713

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

ER -